BioSapien is developing MediChip™, a 3D printed, bio-compatible patch that delivers targeted drug combinations directly to tumor sites, minimizing systemic chemotherapy's harsh side effects. This localized treatment approach enhances patient quality of life and expands surgical options by shrinking tumors effectively.
Funding
Funding not disclosed
Founders
Product
Problem
Systemic chemotherapy, while effective at targeting cancer cells, subjects the entire body to toxic drugs, leading to harsh side effects and diminished quality of life for patients. This approach can also limit treatment options for doctors, especially when uneven cancer growth makes surgery risky.
Solution
BioSapien is developing MediChip™, a 3D-printed, biodegradable mesh designed for localized drug delivery directly to tumor sites. This targeted approach allows for the administration of multiple FDA-approved drugs with greater precision, minimizing systemic side effects and improving patient well-being. By shrinking tumors and easing symptoms, MediChip™ can expand surgical options and provide a first-line treatment for locally advanced gastrointestinal cancers. The platform is designed for sustained drug release, offering increased efficacy and reduced toxicity compared to traditional chemotherapy.
Target Audience
The primary target audience includes cancer patients undergoing chemotherapy, as well as surgeons and oncologists seeking more precise and less toxic treatment options, particularly for gastrointestinal and solid tumors.
Features
- 3D-printed biodegradable mesh for direct drug delivery to tumors
- Localized controlled release of up to five FDA-approved drugs
- Minimizes systemic side effects associated with traditional chemotherapy
- Designed to shrink tumors and ease symptoms, potentially expanding surgical options
- Intended as a first-line treatment for stage III locally advanced gastrointestinal cancer patients during surgery
- Granted global patents with expiration in 2039